Pear Therapeutics Inc - Product Pipeline Analysis, 2018 Update

Published by Global Data on 27th December 2018 | Ref: 1127986 | This Report Is In Stock

$750 | Single User
$1500 | Site License
$2250 | Enterprise License
$750 | Single User
$1500 | Site License
$2250 | Enterprise License



Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive designed for schizophrenia; reCALL using virtual reality exposure therapy to treat combat posttraumatic stress disorder (PTSD); reVIVE against general anxiety disorder; and PEAR-005 to PEAR-011 for treating pain, major depressive disorder, insomnia, Parkinson's disease and inflammatory conditions. Pear Therapeutics reSET, is an FDA-authorized prescription therapeutic for substance use disorder (SUD) used as an outpatient treatment. The company works in partnership with Center for Technology and Behavioral Health, Dartmouth College, Ehave, Inc., Intellectual Ventures Management LLC, Novartis AG, and others. Pear Therapeutics is headquartered in Boston, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Pear Therapeutics Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Pear Therapeutics Inc Company Overview 5

Pear Therapeutics Inc Company Snapshot 5

Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview 5

Pear Therapeutics Inc – Pipeline Analysis Overview 8

Pear Therapeutics Inc - Key Facts 8

Pear Therapeutics Inc - Major Products and Services 9

Pear Therapeutics Inc Pipeline Products by Development Stage 11

Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 13

Pear Therapeutics Inc Pipeline Products Overview 15

Digital Therapeutic - Inflammatory conditions 15

Digital Therapeutic - Inflammatory conditions Product Overview 15

Digital Therapeutic - Major Depressive Disorder 16

Digital Therapeutic - Major Depressive Disorder Product Overview 16

Digital Therapeutic - Oncology 17

Digital Therapeutic - Oncology Product Overview 17

Digital Therapeutic - Parkinson's Disease 18

Digital Therapeutic - Parkinson's Disease Product Overview 18

Digital Therapeutic - Respiratory 19

Digital Therapeutic - Respiratory Product Overview 19

PEAR-003 - Insomnia 20

PEAR-003 - Insomnia Product Overview 20

PEAR-006 - Multiple Sclerosis 21

PEAR-006 - Multiple Sclerosis Product Overview 21

reCALL 22

reCALL Product Overview 22

reVIVE 23

reVIVE Product Overview 23

Thrive 24

Thrive Product Overview 24

Thrive Clinical Trial 25

Pear Therapeutics Inc - Key Competitors 26

Pear Therapeutics Inc - Key Employees 27

Pear Therapeutics Inc - Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Pear Therapeutics Inc, Recent Developments 29

Jan 16, 2018: Magellan Health Continues Innovation and Efforts to Improve Outcomes for Patients with Substance Use Disorder 29

Dec 12, 2017: Pear Therapeutics Wins Fierce Innovation Life Science Award for reSET Prescription Digital Therapeutic 29

Oct 18, 2017: Pear Therapeutics Receives Expedited Access Pathway Designation from FDA for reSET-O Prescription Digital Therapeutic to Treat Opioid Use Disorder 30

Sep 26, 2017: Pear Therapeutics Selected to Participate in the FDA’s Digital Health Software Pre-Cert Pilot Program 30

Sep 14, 2017: FDA permits marketing of mobile medical application for substance use disorder 31

Sep 14, 2017: Pear Therapeutics Obtains FDA Clearance Of The First Prescription Digital Therapeutic To Treat Disease 31

Jul 11, 2017: Enhancing Digital Medicine to Tackle Addiction 32

Aug 25, 2016: The Largest and Longest Study of Patients with Schizophrenia Interacting with Digital Therapeutics Results Released 33

Appendix 34

Methodology 34

About GlobalData 37

Contact Us 37

Disclaimer 37

Additional Details


Global Data

Publisher Information


1127986 | GDME509172PD

Number of Pages


Report Format


This report is published by Global Data

Download Free Report Summary PDF

Pear Therapeutics Inc - Product Pipeline Analysis, 2018 Update [Updated: 27-12-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types


Buy now using our secure payment system.